Natural Progression of Left Ventricular Function following Anthracyclines without Cardioprotective Therapy: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Anthracyclines form the backbone of many systemic chemotherapy regimens but are accompanied by dose-limiting cardiotoxicity. We elucidate the progression and severity of cardiac function over time, in the absence of cardioprotection, which less is known about.

Methods

This PRISMA-guideline-adherent review was registered on PROSPERO (CRD42022373496).

Results

26 studies met the eligibility criteria including a total of 910 patients. The overall reduction in post-anthracycline pooled mean left ventricular ejection fraction (LVEF) in placebo arms of the included randomised-controlled trials was 4.5% (95% CI, 2.6 to 6.4). The trend in LVEF showed a progressive decline until approximately 180 days, after which there was no significant change. Those receiving a cu

SUBMITTER: Lee ARYB 

PROVIDER: S-EPMC9856944 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature